A single hematopoietic stem cell (HSC) is capable of reconstituting hematopoiesis and maintaining homeostasis by balancing self-renewal and cell differentiation. The mechanisms of HSC division balance, however, are not yet defined. Here we demonstrate, by characterizing at the single-cell level a purified and minimally heterogeneous murine Tie2 + HSC population, that these top hierarchical HSCs preferentially undergo symmetric divisions. The induction of mitophagy, a quality control process in mitochondria, plays an essential role in self-renewing expansion of Tie2 + HSCs. Activation of the PPAR (peroxisome proliferator-activated receptor)-fatty acid oxidation pathway promotes expansion of Tie2 + HSCs through enhanced Parkin recruitment in mitochondria. These metabolic pathways are conserved in human TIE2 + HSCs. Our data thus identify mitophagy as a key mechanism of HSC expansion and suggest potential methods of cell-fate manipulation through metabolic pathways.
†
A single hematopoietic stem cell (HSC) is capable of reconstituting hematopoiesis and maintaining homeostasis by balancing self-renewal and cell differentiation. The mechanisms of HSC division balance, however, are not yet defined. Here we demonstrate, by characterizing at the single-cell level a purified and minimally heterogeneous murine Tie2 + HSC population, that these top hierarchical HSCs preferentially undergo symmetric divisions. The induction of mitophagy, a quality control process in mitochondria, plays an essential role in self-renewing expansion of Tie2 + HSCs. Activation of the PPAR (peroxisome proliferator-activated receptor)-fatty acid oxidation pathway promotes expansion of Tie2 + HSCs through enhanced Parkin recruitment in mitochondria. These metabolic pathways are conserved in human TIE2 + HSCs. Our data thus identify mitophagy as a key mechanism of HSC expansion and suggest potential methods of cell-fate manipulation through metabolic pathways. P recise mechanisms enable efficient and regulated hematopoietic stem cell (HSC) renewal versus differentiation, and these processes are coordinated. HSCs must withstand various stresses to maintain hematopoiesis for the duration of their life cycles. The repair or clearance of damage is critical to precisely controlling their cell fates and maintaining stemness upon division, especially during HSC expansion through symmetric self-renewing division. HSC exhaustion can result from defective cellular metabolism and/or impaired autophagy (1-6), a lysosomal degradation pathway that breaks down damaged or unwanted proteins and/or organelles (7) . The FOXO3A (forkhead box O3a)-driven proautophagy program, for example, protects HSCs from metabolic stress (5) . In a similar process in mammary epithelial stemlike cells, older mitochondria are pushed into daughter cells fated to differentiate by asymmetric division (AD), thus maintaining highquality stem cell homeostasis (8) . Despite extensive study of HSC renewal and differentiation, however, much remains unclear regarding the mechanisms of division balance due to the heterogeneity of HSC-enriched fractions.
In searching for a potential HSC marker, we observed high Tie2 levels in the CD34 -HSCenriched compartment (fig. S1A). We therefore established a Tie2-green fluorescent protein (GFP) reporter line (Tie2-reporter mice or Tie2 Tg) to validate Tie2-expression as an HSC marker (fig .  S1 , B and C). Tie2-GFP was specifically enriched in the HSC fraction but was reduced during differentiation, in parallel with mRNA levels ( fig.  S1 , D to G). In addition, the Tie2-GFP + fraction displayed a highly significant (5.75-fold) increase in longterm culture-initiating cell (LTC-IC) frequency relative to the Tie2-GFP -fraction (Fig. 1A) . Singlecell transplantation showed that a high percentage of single Tie2-GFP + cells (68.0%) exhibited reconstitution capacity without lineage bias and maintained high donor chimerism upon secondary transplantation. Donor contribution was observed in all recipients transplanted with three Tie2-GFP + HSCs, whereas 40% showed reconstitution capacity with three Tie2-GFP -HSCs (Fig. 1B and fig. S2 , A to D), demonstrating that Tie2-GFP identifies an HSC fraction with minimal heterogeneity. To accurately supply the bone marrow with individual HSCs, we employed multiphoton microscopy guidance (local transplantation) ( fig. S2E ) to deliver single Tie2-GFP + HSCs near an opening to the marrow of live mice, and we then tracked these cells during subsequent homing to locations some distance from the delivery site ( Fig. 1C and Single-cell gene expression assays showed that a substantial number of genes-including HSC factors and markers (e.g., Tie2, Hif1a, Mpl, and Foxo3a), as well as Pml (promyelocytic leukemia) and its downstream signaling pathways, which regulate fatty acid oxidation (FAO) via Cpt1a (carnitine palmitoyltransferase 1a), Ppard (peroxisome proliferator-activated receptor-delta), and Acox1 (acyl-coenzyme A oxidase1)-were markedly higher in the Tie2-GFP + fraction than the Tie2-GFP -fraction ( the mitochondrial matrix (12) . Our gene expression assays revealed higher expression of mitochondrial autophagy (mitophagy)-related genes, including Parkin (Park2), Pink1 (PTEN-induced putative kinase 1), Optineurin, Tom 7, Map1lc3a (Lc3), and p62/Sqstm1, in Tie2-GFP + HSCs at steady-state conditions. Most of these genes were further up-regulated by activation of the PPAR-FAO pathway ( Fig. 2A and fig. S5 , D to F). To assess whether mitophagy-related genes are regulated by the PPAR-FAO pathway at the transcriptional level, Pink1-luciferase reporters were used. A PPARd agonist transactivated Pink1 reporters, which were reduced by FAO inhibition or mutation of FOXO-response elements. Foxo3a was up-regulated in HSCs upon treatment with a PPARd agonist, and this process was attenuated by the ablation of Ppard or Cpt2, which are FAOrelated genes. These data suggest that the PPAR-FAO pathway transcriptionally regulates PINK1, in part through FOXO3a ( fig. S6) .
We then sought to determine whether PPARdinduced mitophagy correlates with a specific metabolic state or profile. Cellular FAO activity was specifically enhanced after PPARd agonist treatment and was accompanied by Pink1, whereas glucose uptake or levels of pyruvate and tricarboxylic acid cycle metabolites were not altered ( fig. S7, A  to D) . PPARd agonists also enhanced mitophagy, with the increased colocalization of Tom20 (translocase of outer membrane 20) with LAMP1 (lysosomalassociated membrane protein 1). Flux analyses were then performed to quantify mitochondrial turnover in lysosomes (the organelles where mitophagy occurs) by evaluating the accumulation of Tom20 in the presence of leupeptin, an inhibitor of lysosomal proteolysis. Pharmacological PPAR-FAO activation enhanced the net mitochondrial flux toward lysosomal degradation. These data strongly suggest that the PPAR-FAO pathway activates mitophagy (Fig. 2, B and C) .
Other findings supported the enhancement of mitophagy by a PPAR agonist, including increased colocalization of Parkin with pyruvate dehydrogenase (PDH), a matrix mitochondrial protein. Mitophagy enhancement was again confirmed in GW501516-treated HSCs by the increased colocalization of Parkin with both Tom20 and the autophagosome marker LC3 (figs. S7E and S8, A to D). To explore another mitophagy indicator, mitochondrial DNA (mtDNA) nucleoids were quantified after mitochondrial damage with oligomycin and antimycin A. GW501516-treated HSCs were nearly devoid of mtDNA and exhibited increased net mtDNA flux, whereas mtDNA was still partially retained in control HSCs (Fig. 2D) . Thus, damaged mitochondria are cleared more quickly due to enhanced mitophagy activation in Tie2-GFP + HSCs treated with a PPAR agonist.
Hematopoiesis-specific Ppard conditional knockout mice were then generated. Pparddeleted HSCs exhibited neither enhanced Tom20 and Parkin colocalization nor increased mitochondrial net flux after PPARd agonist treatment, although these agonists stimulated mitophagy in wild-type HSCs, and a mitochondrial uncoupler, carbonyl cyanide m-chlorophenylhydrazone (CCCP), induced mitophagy in both genotyped HSCs ( fig. S8E ). Conditional heterozygous deletion of Cpt2 partially but significantly attenuated the enhanced Parkin recruitment in mitochondria induced by a PPAR agonist ( fig. S8F ). Taken together, these direct genetic approaches reveal that PPARd agonists stimulate mitophagy in a PPAR-FAO-dependent manner.
To test whether mitophagy is critical for Tie2-GFP + HSC expansion, Parkin and Pink1 were first silenced by RNA interference-mediated knockdown. siPark2 decreased net mitochondrial flux (a hallmark of mitophagy) in GW501516-treated HSCs, as indicated by decreased colocalization of Tom20 and PDH with LAMP1, whereas cell death, proliferation rate, FAO activity, and Cdk6 levels were not altered (Fig. 3A and figs. S7A and S9) . Parkin-knockdown in GW501516-treated HSCs led to accumulating signals of Tom20 and PDH, as well as reduced colocalization of LAMP1 with LC3 ( fig. S10 , A to C). mtDNA was retained in Parkin-silenced HSCs, and these cells were refractory to PPAR agonist treatment (Fig. 3B and  fig. S10D ). These data suggest that Parkin has an essential role in PPAR-FAO-induced mitophagy.
Because Pink1 is known to be essential for mitophagy and Pink1 levels were increased by PPAR-FAO activation, we next assessed the effect of Pink1 knockdown on the process. Pink1 silencing reduced Tom20 colocalization with both LAMP1 and Parkin and decreased net flux of mitochondria in GW501516-treated HSCs, accompanied by accumulating Tom20 signals. mtDNA was also retained in Pink1-silenced HSCs (Fig. 3,  B and C, and fig. S10, D to G) . Consequently, Parkin and Pink1 play important roles in PPAR-FAO-induced mitophagy in HSCs.
We then explored potential clinical applications of pharmacological FAO modulation in human hematopoiesis. TIE2 expression is enriched in the HSC fraction, and TIE2-positivity enhances LTC-IC frequency and in vivo repopulation capacity in human bone marrow ( fig. S11 , A to G). GW501516 enhances LTC-IC frequency with mitophagy activation, whereas low doses of an FAO inhibitor reduce its capacity. Fatty acid metabolism can therefore control self-renewal capacity and the cell fates of human HSCs (Fig.  3D and fig. S11, H to J) .
Finally, we explored the effects of FAO-induced mitophagy on Tie2-GFP + HSC expansion. In vivo paired daughter cell (PDC) assays can determine the division patterns of HSCs retrospectively, by assessing the reconstitution capacity of each daughter cell (3, 13) . In vivo PDC assays revealed that Tie2-GFP + HSCs preferentially undergo symmetric division (SD) (in 20 out of 27 divisions, or 74.1%, both daughter cells showed a reconstitution capacity) rather than AD or symmetric commitment [(SC), both daughter cells exhibited no reconstitution capacity], whereas Tie2-GFP -HSCs undergo either AD or SC (Fig. 4, A to C, and fig.  S12 ). To further test the restoration capacity of hematopoiesis by single Tie2-GFP + HSCs, we performed transplantation assays under highstress conditions, as are found in single-cell transplantation without supporting cells. The survival ratio after single Tie2-GFP + HSC transplantation was 85.7%, whereas no recipients of single Tie2-GFP -HSCs survived (Fig. 4D and fig. S13 , A and B). Functional HSCs are present in the Tie2-GFP -fraction, but they fail to adequately respond to the demand for hematopoietic recovery under high-stress conditions without the enhanced symmetric expansion provided by Tie2-GFP + HSCs. As expected, PPAR-FAO activation increased the number of Tie2-GFP + cells in vitro with an increased rate of SD ( fig. S13, C to G) . Tie2-GFP + HSC numbers were increased in comparison with the original number of transplanted donor cells in recipients and were further increased by PPARd agonist treatment (about a fourfold increase). Furthermore, PPARd agonist treatment expanded Tie2-GFP + HSCs under physiological stress, as induced by pIpC (Fig. 4E and figs. S3B and S13H) .
However, silencing Park2 or Pink1 not only abrogated the expansion of Tie2-GFP + cells in vitro but also inhibited their maintenance ( fig. S13I ). Most single Parkin-silenced Tie2-GFP + cells failed to show reconstitution capacity (92.3%), whereas the majority of control Tie2-GFP + cells (66.7%) exhibited this capacity (Fig. 4F and fig.  S13J ). Pink1 −/− HSCs failed to adequately respond to the demand for hematopoietic recovery under high-stress conditions, even though a PPARd agonist was administered ( fig. S13K ). In conclusion, Tie2-GFP + HSCs can maintain stem cell potential during cell cycling due to high mitochondrial clearance through mitophagy and up-regulation of Parkin and Pink1 (fig. S14 ). Our data from this SCIENCE sciencemag.org highly purified HSC fraction identifies mitochondrial clearance by induction of mitophagosome formation as a key mechanism in maintaining stemness. (1) . Collectively, these properties prevent optimal control of persisting pathogens and tumors. Blocking the PD-1:PD-L1 pathway can reinvigorate exhausted CD8 T cells (T EX ), improving effector functions and enhancing viral and tumor control (1) . Recently developed inhibitors of the PD-1 and cytotoxic T lymphocyteassociated protein 4 (CTLA-4) pathways represent a new paradigm in cancer treatment (2) (3) (4) . Although promising, the majority of patients fail to develop durable responses, and most eventually progress (2-4). Thus, it is unclear whether blocking PD-1 can promote long-lasting improvements and immunological memory development in T EX .
To address this question, we analyzed the cellular, transcriptional, and epigenetic changes associated with PD-1 pathway blockade using the mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection ( fig. S1 , A to C) (5, 6) . After treatment with antibodies against PD-L1 (anti-PD-L1), 1080 genes were up-regulated and 1686 genes were down-regulated [P < 0.05, log 2 fold change (LFC) ≥ 0.2] (Fig. 1A, fig. S1D , and table S1). Previous studies identified transcriptional (7) or cellular (8, 9) changes in metabolic pathways after PD-1 pathway blockade. Indeed, several metabolic genes were altered following PD-L1 blockade (table S1). Gene Set Enrichment Analysis (GSEA), however, identified more prominent changes in cell division pathways (Fig. 1B and table S2 ) (5, 10) . In addition, many effector-related genes were biased toward the anti-PD-L1 group (Fig. 1, C and D, and table S3). Other genes of interest included Cxcl9, Il1r2, and Il7r (up-regulated) and Klra9, Tnfrsf9, and Cd200r2 (down-regulated) ( fig. S1D and table  S1 ). Using leading-edge metagene (LEM) analysis (11), we identified two metagenes in anti-PD-L1-treated T EX compared to control T EX ; one corresponding to leukocyte activation and one to cell cycle ( Fig. 1E; fig. S1 , E and F; and table S4). The anti-PD-L1-treated T EX metagenes displayed some overlap with effector T cells (T EFF ), largely driven by cell cycle pathways, but minimal overlap with T MEM (Fig. 1E and table S4 ), suggesting limited acquisition of memory potential upon T EX reinvigoration.
PD-1 pathway blockade can reactivate functions in T EX , but whether reinvigoration is sustained is unclear. There was a robust reinvigoration of T EX , as expected (Fig. 1, F and G, and figs. S1, A and B, and S2) (5), and expansion peaked~3 weeks after initiation of blockade. By 8 to 11 weeks after treatment, however, this reinvigoration was lost, and the quantity, proliferation, effector function, and inhibitory receptor expression of LCMV-specific CD8 T cells in the anti-PD-L1-treated mice were comparable to those in control-treated mice (Fig.  1, F to H, and figs. S2 to S4). Moreover, although anti-PD-L1 treatment reduced viral load immediately after treatment, 4 months later, viral load was similar to that in control-treated mice (Fig. 1I) . Lastly, 18 to 29 weeks after cessation of blockade, the transcriptional profiles of control-and anti-PD-L1-treated groups were similar (Fig. 1J, figs . S5 and S6, and tables S5 and S6). Collectively, these data indicate that when antigen concentration remains high, T EX that were reinvigorated by PD-1 pathway blockade become "reexhausted."
One possible reason the effects of PD-L1 blockade were not sustained is that the infection persisted. We hypothesized that if the infection were cleared, anti-PD-L1 might induce differentiation into T MEM .
